Pricing

Intercept Pharmaceuticals Inc (ICPT)

followers ·
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Jerome B. Durso
Employees: 440
Web site: interceptpharma.com
305 MADISON AVENUE, MORRISTOWN, NJ, 07960
646-747-1000

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

All 13F Filers Prior Change Hedge Funds 1 Prior Change
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available